A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer

Neoantigen vaccines have been enthusiastically pursued for personalized cancer immunotherapy while vast majority of neoantigens have no or low immunogenicity. Here, a bi-adjuvant neoantigen nanovaccine (banNV) that codelivered a peptide neoantigen (Adpgk) with two adjuvants [Toll-like receptor (TLR)...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Sci Adv
Autores principales: Ni, Qianqian, Zhang, Fuwu, Liu, Yijing, Wang, Zhantong, Yu, Guocan, Liang, Brian, Niu, Gang, Su, Ting, Zhu, Guizhi, Lu, Guangming, Zhang, Longjiang, Chen, Xiaoyuan
Formato: Artigo
Lenguaje:Inglês
Publicado: American Association for the Advancement of Science 2020
Materias:
Research Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7080439/
https://ncbi.nlm.nih.gov/pubmed/32206706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aaw6071
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares